Closing the Gap in Hemophilia Care: Therapeutic Advances in Hemophilia A and B

Closing the Gap in Hemophilia Care: Therapeutic Advances in Hemophilia A and B 

On-Demand 1.5-hour Accredited Webcast

Faculty Presenters

James Kenney, RPh, MBA
President
JTKENNEY, LLC
Waltham, Massachusetts

Leslie Ward, PharmD, BCPS, BCOP
Clinical Pharmacist, Benign Hematology
UVA Specialty Pharmacy
UVA Health
Charlottesville, Virginia
 
Program Description
Hemophilia is a serious coagulation disorder affecting approximately 1.1 million males worldwide. It is a genetic disorder characterized by variants in clotting factors and is associated with bleeding and potential joint damage. Hemophilia can impact patient quality of life due to complications, treatments, and health care-associated costs. This activity will detail the pathophysiology of both hemophilia A and B, as well as historic and emerging treatments used in clinical practice for both variants of this condition. Additionally, the overall impact of hemophilia on health care use will be discussed, with an emphasis on costs associated with care.

Target Audience: Managed care, oncology, and specialty pharmacists
Type of Activity: Application
Release date: May 18, 2021
Expiration date: May 18, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Explain the etiology and pathophysiology of hemophilia A and B
• Differentiate current treatment options for the management of hemophilia A and B, with an emphasis on emerging gene and biologic therapies
• Analyze the value proposition of available therapies in the care of patients with hemophilia
• Compare the clinical efficacy of treatment strategies used in the management of hemophilia and the impact on health care utilization

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-208-H01-P. The activity is available for CE credit through May 18, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

James Kenney, RPh, MBA, and Leslie Ward, PharmD, BCPS, BCOP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms